Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)

Exclusion Criteria

• •1. Previous removal of both ovaries or ovarian ablation (such as bilateral ovarian radiotherapy)
• •2. Patients who have previously received immunotherapy or chemotherapy prior to registration
• •3. Receiving or planned to receive adjuvant endocrine therapy Note: patients using GnRH agonist for POI prevention are not excluded
• •4. Post-menopausal as defined by the investigator
• •5. Presence of any psychological, social, geographical, or other condition for which, in the opinion of the site Investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments